p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation.

about

p53 protein expression in patients with myelodysplasia treated with allogeneic bone marrow transplantation.

Item

http://www.wikidata.org/entity/Q38739506

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

p53 protein expression in pati ...... c bone marrow transplantation.

@en

type

Item

label

p53 protein expression in pati ...... c bone marrow transplantation.

@en

prefLabel

p53 protein expression in pati ...... c bone marrow transplantation.

@en

P1476

p53 protein expression in pati ...... c bone marrow transplantation.

@en

P2093

Achille Pich

http://www.w3.org/2001/XMLSchema#string

Laura Davico Bonino

http://www.w3.org/2001/XMLSchema#string

Laura Godio

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical effect of point mutations in myelodysplastic syndromes

p53 protein expression independently predicts outcome in patients with lower-risk myelodysplastic syndromes with del(5q).

Prognostic classification and risk assessment in myelodysplastic syndromes.

Cytogenetic and molecular abnormalities in myelodysplastic syndrome.

Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia.

p53 expression in myeloid cells of myelodysplastic syndromes. Association with evolution of overt leukemia.

Response to azacitidine is independent of p53 expression in higher-risk myelodysplastic syndromes and secondary acute myeloid leukemia.

TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.

Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes.

Expression of p53, MDM2, p21waf1, bcl-2, and retinoblastoma gene proteins in myelodysplastic syndrome after autologous bone marrow transplantation for lymphoma.

P304

876-880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1225

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28588781

http://www.w3.org/2001/XMLSchema#string

P932

5451870

http://www.w3.org/2001/XMLSchema#string